Japanese Encephalitis Virus Envelope protein antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Japanese Encephalitis Virus Envelope protein antibodies pairs and antigen for animal health (animal Swine/Porcine/Pig infectious disease Japanese encephalitis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Swine/Porcine/Pig disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P291-Tg001-Ag01	Recombinant Japanese Encephalitis Virus Envelope protein protein	$3090.00
GMP-VT-P291-Tg001-Ab01	Anti-Japanese Encephalitis Virus Envelope protein mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P291-Tg001-Ab02	Anti-Japanese Encephalitis Virus Envelope protein mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P291-Tg001-Ab03	Anti-Japanese Encephalitis Virus Envelope protein human monoclonal antibody (mAb)	$3090.00
GMP-VT-P291-Tg001-Ab04	Anti-Japanese Encephalitis Virus Envelope protein human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P291-Tg001-Ag01
Product Name	Recombinant Japanese Encephalitis Virus Envelope protein protein
Pathogen	Japanese Encephalitis Virus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Japanese Encephalitis Virus Envelope protein antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Japanese Encephalitis Virus level test of animal Swine/Porcine/Pig infectious disease with Japanese encephalitis.
Tag	His
Product description	Recombinant Japanese Encephalitis Virus Envelope protein proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P291-Tg001-Ab01,GMP-VT-P291-Tg001-Ab02
Pathogen	Japanese Encephalitis Virus
Product Name	Anti-Japanese Encephalitis Virus Envelope protein mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Japanese Encephalitis Virus Envelope protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Japanese Encephalitis Virus antibodies in Japanese Encephalitis Virus level test of animal Swine/Porcine/Pig infectious disease with Japanese encephalitis.
Product description	Anti-Japanese Encephalitis Virus Envelope protein mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Japanese Encephalitis Virus antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P291-Tg001-Ab03,GMP-VT-P291-Tg001-Ab04
Pathogen	Japanese Encephalitis Virus
Product Name	Anti-Japanese Encephalitis Virus Envelope protein human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Japanese Encephalitis Virus Envelope protein antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Japanese Encephalitis Virus antibodies in Japanese Encephalitis Virus level test of animal Swine/Porcine/Pig infectious disease with Japanese encephalitis.
Product description	Anti-Japanese Encephalitis Virus Envelope protein mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Japanese encephalitis (JE) is a viral disease that is caused by the Japanese encephalitis virus (JEV), which primarily affects the central nervous system. It is a severe neurological disease that can lead to brain damage or death, and it is endemic in several countries in Asia-Pacific, including India, China, and Southeast Asian countries.

JEV is classified as a member of the Flaviviridae family, which includes other viruses such as dengue, yellow fever, and West Nile viruses. JEV has a spherical shape with a diameter of around 40-50 nanometers and contains a single-stranded RNA genome that encodes for several structural and non-structural proteins.

The envelope (E) protein, which is present on the surface of the virus, plays a crucial role in JEV's entry into host cells and attachment to the target cell receptors. The capsid (C) protein forms the protective coat around the RNA genome inside the virion. The membrane (M) protein is responsible for the formation of viral particles, while the non-structural (NS) proteins perform various functions related to viral replication and evasion of the host immune system.

JEV is primarily transmitted by mosquitoes of the genus Culex, which typically breed in paddy fields, swamps, and other stagnant water bodies. The virus replicates in the mosquito's salivary glands and can be transmitted to humans through a mosquito bite. JEV infection can also occur through consumption of contaminated food or water, or occasionally through organ transplantation or blood transfusion from an infected person.

In humans, JEV can cause a range of clinical manifestations, from asymptomatic infections to severe neurological complications such as meningitis, encephalitis, and acute flaccid paralysis. Japanese encephalitis is characterized by the inflammation of the brain tissue, which can result in seizures, confusion, and altered consciousness, with mortality rates ranging from 10-30% in severe cases.

Diagnosis of JEV infection is typically based on clinical symptoms and laboratory tests. Nucleic acid amplification tests (NAATs) such as real-time reverse transcription polymerase chain reaction (RT-PCR) can detect JEV RNA in blood or cerebrospinal fluid samples with high sensitivity and specificity. Serological tests such as enzyme-linked immunosorbent assay (ELISA) can also detect the presence of JEV-specific antibodies in the patient's serum. These diagnostic methods are essential for accurate diagnosis, which enables effective treatment and prevention strategies.

Treatment options for Japanese encephalitis are limited, and supportive care is the primary approach. Antiviral drugs such as ribavirin and interferon-alpha have shown some effectiveness in vitro, but their clinical benefits for JE patients need further evaluation. The most effective way to prevent JEV infection is through vaccination. Several vaccines are available that offer long-term immunity against JE, including inactivated vaccines, live attenuated vaccines, and recombinant vaccines.

In conclusion, the Japanese encephalitis virus is a flavivirus that primarily affects the central nervous system and is primarily transmitted by mosquitoes. While JEV is endemic in several Asian-Pacific countries, vaccination and diagnostic methods play a crucial role in controlling the spread of the disease.

About GDU